Summary

ARTS-HF study demonstrated that finerenone had a comparable efficacy with eplerenone in reducing N-terminal pro-brain natriuretic peptide and a greater efficacy in reducing the incidence of the composite of all-cause death, cardiovascular hospitalization, or emergency presentation for worsening chronic heart failure in patients with heart failure with reduced ejection fraction and type 2 diabetes or chronic kidney disease. However, caution is required in interpreting the results because it was an exploratory, underpowered study.